Why Qiagen QuantiFERON-TB Gold Plus is quietly changing latent TB screening

Qiagen's QuantiFERON-TB Gold Plus turns a routine blood draw into a precise test for latent tuberculosis infection. What matters in everyday lab use, where the kit shines, and where its limitations start to show.

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 02:49. Details in the imprint.

With the QuantiFERON-TB Gold Plus kit, Qiagen turns a small rack of blood collection tubes into a quiet, highly standardized gatekeeper against latent tuberculosis infection in clinics and public health labs. The promise is clear-cut results without the guesswork of skin tests.

What the kit actually does

In practice, QuantiFERON-TB Gold Plus is an interferon-gamma release assay, or IGRA, built around four specialized blood collection tubes that are incubated to provoke a targeted immune response to Mycobacterium tuberculosis antigens. After incubation, laboratories quantify interferon-gamma in plasma using an ELISA readout.

The set-up aims to detect latent tuberculosis infection rather than active disease and is designed to work as a modern alternative to the tuberculin skin test. Because the assay uses TB-specific antigens, it is intended to avoid the false-positive results that BCG vaccination can trigger in skin testing.

How it fits into daily lab workflow

For lab teams, the first contact with QuantiFERON-TB Gold Plus is usually at sample collection, where phlebotomists draw whole blood directly into the color-coded tubes and invert them several times to mix. The tubes then need incubation at 37 °C, typically within 16 hours of collection, for a defined period to stimulate T cells.

Once incubation is complete, the tubes are centrifuged to separate plasma, and the interferon-gamma concentration is measured via a microplate ELISA that can be read on standard plate readers. Qiagen offers dedicated analysis software that interprets raw optical-density data and automatically flags positive, negative, and indeterminate results according to the package insert.

Strengths compared with skin tests

Clinicians and occupational-health teams often reach for QuantiFERON-TB Gold Plus because it requires only a single patient visit for blood draw, unlike the tuberculin skin test that demands a follow-up reading visit. The assay also avoids subjective visual interpretation, substituting it with numerical interferon-gamma values and standardized cutoffs.

That technical design is particularly attractive where BCG vaccination is common, as the TB-specific antigens used in the test are reported not to cross-react with most non-tuberculous mycobacteria or the BCG strain. This reduces the risk of unnecessary follow-up and treatment for people who simply carry a vaccine-induced immune memory.

Limitations that labs need to respect

Despite its strengths, QuantiFERON-TB Gold Plus is not a test for active TB disease and cannot replace culture, molecular assays, or imaging where symptoms are present. The manufacturer stresses that results should always be interpreted in the context of clinical and epidemiological risk factors rather than in isolation.

The workflow also has built-in fragilities: delayed incubation, improper tube filling, or inadequate mixing can all lead to indeterminate results. Smaller facilities without on-site incubators or ELISA capacity may need to coordinate tightly with central labs to keep pre-analytical variables under control.

Regulatory footprint and where it is used

Qiagen highlights that QuantiFERON-TB Gold Plus is approved by the US Food and Drug Administration as an aid in diagnosing M. tuberculosis infection, both latent and active, when used alongside other diagnostic information. In Europe, the assay carries CE marking for in vitro diagnostic use, anchoring its role in national TB guidelines and screening programs.

The test has been integrated into screening protocols for healthcare workers, migrants from high-incidence regions, and patients starting immunosuppressive therapy in many health systems. That makes it a steady, if unobtrusive, revenue driver in Qiagen's diagnostics portfolio.

Pricing, economics, and who it targets

Pricing for QuantiFERON-TB Gold Plus varies by region and contract structure, but hospital and reference laboratories typically purchase the assay as kits of tubes plus ELISA components through distributors or directly from Qiagen's sales teams. The economics hinge on batch size, as running multiple samples per plate helps dilute labor and equipment costs.

The target users are clear: medium to large clinical laboratories that manage occupational screening, immigration-related testing, or pre-biologic therapy work-ups at scale. For individual patients, the experience is straightforward - a regular blood draw with laboratory turnaround measured in days rather than a slow drip of multiple visits.

Where QuantiFERON-TB Gold Plus sits in Qiagen's story

QuantiFERON-TB Gold Plus is more than a single diagnostic kit; it embodies Qiagen's strategy of combining sample collection, standardized reagents, and data analysis software into integrated testing workflows across infectious disease and beyond. That approach locks customers into platforms that promise reproducibility and regulatory clarity.

All told, the test anchors Qiagen's presence in global TB control efforts and offers a recurring stream of consumable sales that tends to be less volatile than instrument demand. For investors, the product sits alongside sample-prep and syndromic testing lines as an indicator of how resilient Qiagen's diagnostics franchise can be in varying macro cycles.

Qiagen context and stock reference

Qiagen, headquartered in Hilden and Venlo, has built a broad portfolio around molecular diagnostics, sample preparation, and life-science tools, with QuantiFERON-TB Gold Plus as one of its most visible infectious-disease offerings. Shares of Qiagen N.V. (NL0012169213) trade on Xetra in euros.

Key facts on QuantiFERON-TB Gold Plus

• Product: QuantiFERON-TB Gold Plus
• Manufacturer: Qiagen N.V.
• Category: Software/Service/Subscription - diagnostic test kit and analysis software
• Launch: Commercially introduced in the mid-2010s as an evolution of earlier QuantiFERON-TB assays
• RRP / Price: Contract and region dependent, typically sold as multi-test kits to clinical laboratories
• Availability: Distributed through Qiagen sales channels and diagnostic distributors in North America, Europe, and other TB-screening markets
• Target group: Clinical laboratories performing latent TB screening for healthcare workers, migrants, and high-risk patients
• Highlight / USP: Single-visit blood test that minimizes BCG-related false positives compared with tuberculin skin testing

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.